iBio (IBIO) Income towards Parent Company (2010 - 2026)
iBio's (IBIO) quarterly Income towards Parent Company came in at -$7.8 million in Q1 2026, down 58.63% year-on-year from -$19.0 million in Q1 2025, and up 13.68% on a QoQ basis from -$9.1 million in Q4 2025.
iBio (IBIO) Income towards Parent Company (2010 - 2026) Analysis & Trends
iBio (IBIO) has 17 years of Income towards Parent Company data on file, last reported at -$7.8 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 58.63% year-over-year to -$7.8 million in Q1 2026; TTM through Mar 2026 was -$27.8 million, a 54.9% decrease from a year earlier, with the FY2025 full-year figure at -$81.6 million, down 761.76% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$7.8 million, up from -$9.1 million in the prior quarter.
- Over the last five years, Income towards Parent Company for IBIO reached as high as -$537000.0 in Q1 2024 and fell as low as -$23.0 million in Q4 2022.
- Historically, Income towards Parent Company has averaged -$5.8 million across 5 years, with a median of -$4.9 million in 2025.
- Across the five-year window, Income towards Parent Company soared 93.66% in 2023 and sank 821.42% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$23.0 million in 2022, then jumped by 83.81% to -$3.7 million in 2023, then dropped by 19.47% to -$4.4 million in 2024, then tumbled by 104.43% to -$9.1 million in 2025, then climbed by 13.68% to -$7.8 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$7.8 million in Q1 2026, -$9.1 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.85 Mn |
| Dec 31, 2025 | -9.09 Mn |
| Sep 30, 2025 | -5.72 Mn |
| Jun 30, 2025 | -5.09 Mn |
| Mar 31, 2025 | -4.95 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -537,000.00 |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -672,000.00 |
| Jun 30, 2023 | -1.10 Mn |
| Mar 31, 2023 | -1.02 Mn |
| Dec 31, 2022 | -22.99 Mn |
| Sep 30, 2022 | -10.59 Mn |
| Jun 30, 2022 | -6.67 Mn |
| Mar 31, 2022 | -5.64 Mn |
| Dec 31, 2021 | -4.73 Mn |
| Sep 30, 2021 | -3.75 Mn |
| Jun 30, 2021 | -10.09 Mn |